Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD

Status unconfirmed

Conditions studied: Huntington Disease

In brief

SHIELD HD is an international, multisite, prospective, longitudinal cohort natural history study to assess the natural history of HD and its biomarkers that are associated with modulation of the number of cytosine-adenine-guanine (CAG) repeats in the mutant Huntingtin (HTT) gene. Approximately 60 patients will be enrolled into the study and followed for up to 24 months at clinical sites in North America and Europe. The results of this study will inform assessments for a future interventional treatment trial.

Key facts

Study ID

NCT04406636

Run by

CHDI Foundation, Inc.

People needed

70

Starts

2020-05-19

Expected to finish

2023-04-01

Last updated by the study team

2022-09-23

Who can join

Age: 18 and older, up to 63. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California, San Diego (UCSD) — San Diego, California, United States
• Rocky Mountain Movement Disorders Center — Englewood, Colorado, United States
• Beth Israel Deaconess — Boston, Massachusetts, United States
• Columbia University — New York, New York, United States
• Inland Northwest Research — Spokane, Washington, United States
• Centre for Movement Disorders — Toronto, Ontario, Canada
• North York General Hospital — Toronto, Ontario, Canada
• ICM - Institut du Cerveau et de la Moelle épinière — Paris, France
• George-Huntington-Institut (GHI) — Münster, Germany
• University College London - Institute of Neurology & The National Hospital for Neurology and Neurosurgery — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.